IL6 and in situ carcinoma: The TOE + CIS treatment resulted in significant improvements: NF-κB (−12%), TNF-α (−8%), IL-6 (−16%), MDA (−18%), TOS (−20%), and TAS (+28%,p < 0.05), suggesting reduced neuroinflammation.